On March 14, 2026, Bluejay Diagnostics, Inc. (the "Company") entered into a securities purchase agreement (the "Agreement") with several purchasers, including key executives and board members. The Company issued and sold an aggregate of 62,500 shares of its common stock at a price of $2.00 per share, resulting in total gross proceeds of $125,000. The transaction closed on March 17, 2026. The purchasers included Neil Dey, the Company's President and CEO, and other board members, each acquiring 12,500 shares for their own accounts. This private placement was conducted under the exemption provided by Section 4(a)(2) of the Securities Act, meaning the securities were not registered and were sold to accredited investors without general solicitation. The Company has not agreed to provide registration rights for these securities, which may limit their liquidity in the market. This capital infusion is expected to support the Company's ongoing operations and strategic initiatives, although the immediate impact on stock price remains to be seen.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.